Photocure leverages EAU 2026 trials to cement role in precision bladder cancer care

An announcement from Photocure ASA ( (PHCUF) ) is now available.

Photocure ASA, a specialist in bladder cancer diagnostics with its Hexvix/Cysview blue light cystoscopy technology, is expanding its clinical and educational reach in uro-oncology through high-profile participation at the 2026 European Association of Urology congress in London. By positioning Hexvix at the center of efforts to improve detection and resection of non-muscle invasive bladder cancer, the company reinforces its role in a market where recurrence rates and treatment costs remain among the highest in oncology.

At EAU 2026, Photocure is supporting two “trial in progress” studies that test how combining advanced imaging, blue light cystoscopy and genomic urinary biomarkers can refine bladder cancer staging, reduce the need for second-look surgeries and improve assessment of minimal residual disease in high-risk patients. Alongside these trials, the company is amplifying its presence through educational initiatives and a joint scientific event with medac on optimizing bladder cancer care, underlining a strategic push toward personalized, data-driven treatment pathways that could strengthen its clinical relevance and stakeholder value across European and global markets.

More about Photocure ASA

Photocure ASA is a Norway-based specialty pharmaceuticals company focused on uro-oncology, best known for its Hexvix/Cysview (hexaminolevulinate HCl) product used in blue light cystoscopy to improve detection and resection of bladder tumors. The company commercializes this diagnostic imaging agent in the U.S. and Europe and through partners in China, Chile, Australia, New Zealand and Israel, targeting the high-cost, high-recurrence global bladder cancer market.

YTD Price Performance: -5.46%

Average Trading Volume: 77,128

Current Market Cap: NOK1.8B

For detailed information about PHCUF stock, go to TipRanks’ Stock Analysis page.